[Skip to Navigation]
Views 3,256
Citations 0
News From the Centers for Disease Control and Prevention
January 14, 2020

New Malaria Option

JAMA. 2020;323(2):112. doi:10.1001/jama.2019.20669

A newer antimalaria medication with a simplified dosing regimen may be useful in US patients as prophylaxis or as an antirelapse treatment, according to a review in the Morbidity and Mortality Weekly Report.

The US Food and Drug Administration approved tafenoquine in 2018 as prophylaxis for individuals traveling to malaria-endemic areas and for antirelapse therapy for people infected with the Plasmodium vivax malaria parasite. Previously, only primaquine was available for antirelapse therapy.